Risk of postacute sequelae of COVID-19 and oral antivirals in adults aged over 60 years: A nationwide retrospective cohort study

Risk of postacute sequelae of COVID-19 and oral antivirals in adults aged over 60 years: A nationwide retrospective cohort study

Objectives: To investigate the association between oral antiviral administration and postacute sequelae of COVID-19 (PASC) risk in Korea. Methods: This retrospective cohort study used data from the Korea Disease Control and Prevention Agency and the Health Insurance Review and Assessment Service. We...

Full description

Saved in:

Bibliographic Details
Main Authors:	Hyejin Joo, Eunji Kim, Kyungmin Huh, Gi Hwan Bae, Hyungmin Lee, Jungyeon Kim, Dong-Hwi Kim, Min-Gyu Yoo, Il Uk Jo, Poong Hoon Lee, Geun Woo Lee, Hee Sun Jung, Jaehun Jung
Format:	Article
Language:	English
Published:	Elsevier 2025-05-01
Series:	International Journal of Infectious Diseases
Subjects:	COVID-19 Antiviral agents Postacute sequelae of COVID-19 (PASC) Nirmatrelvir/ritonavir Molnupiravir Retrospective cohort study
Online Access:	http://www.sciencedirect.com/science/article/pii/S1201971225000736
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Postacute Sequelae of COVID-19 in Pediatric Patients Within the United States: A Scoping Review
by: Christine M. Miller, et al.
Published: (2024-12-01)

Short- and long-term comparative effectiveness of nirmatrelvir/ritonavir and molnupiravir in asthma patients: a cohort study
by: Guozhang Lin, et al.
Published: (2025-02-01)

Real-world effectiveness and economic analysis of nirmatrelvir/ritonavir, remdesivir, and molnupiravir for treatment of COVID-19 among ambulatory patients in Thailand
by: Sirapat Korwiwattanakan, et al.
Published: (2025-08-01)

CURRENT ASPECTS OF ETIOTROPIC COVID-19 THERAPY
by: D. N. Zemskov, et al.
Published: (2022-12-01)

Effectiveness of nirmatrelvir/ritonavir and molnupiravir on post-COVID-19 outcomes among outpatients: a target trial emulation investigation
by: Yuchen Wei, et al.
Published: (2025-12-01)

Molnupiravir and Nirmatrelvir/Ritonavir: The New Available Antiviral Options for COVID-19
by: Samuel Theodorus Sutanto, et al.
Published: (2023-01-01)

Safety and tolerability of molnupiravir and nirmatrelvir/ritonavir in patients with advanced chronic kidney disease and kidney failure; a cohort study
by: Rani Sawtell, et al.
Published: (2025-12-01)

Carboxylesterase Factors Influencing the Therapeutic Activity of Common Antiviral Medications Used for SARS-CoV-2 Infection
by: Yue Shen, et al.
Published: (2025-06-01)

Application of nirmatrelvir/ritonavir for the treatment of severe COVID-19 in a 3-year-old child
by: Xia Wang, et al.
Published: (2024-11-01)

Postacute Sequelae From SARS-CoV-2 at the University of Illinois Hospital and Clinics: An Examination of the Effects of Long COVID in an Underserved Population Utilizing Manual Extraction of Electronic Health Records
by: John Musachia, et al.
Published: (2025-06-01)

Clinical Benefits of Sustained Oral Nirmatrelvir/Ritonavir Use for the Outpatient Treatment of COVID-19: Findings from the Taiwanese Health Authority Perspective Using a Decision Tree Modeling Approach
by: Matthew Sussman, et al.
Published: (2024-11-01)

Efficacy of Nirmatrelvir tablet/Ritonavir tablet in patients infected with COVID-19 aged 90 years and older
by: WEI Xueman, et al.
Published: (2025-05-01)

Effectiveness and safety of azvudine versus nirmatrelvir/ritonavir in hospitalized patients with COVID-19
by: Jin Yang, et al.
Published: (2025-05-01)

Long COVID across SARS‐CoV‐2 variants: Clinical features, pathogenesis, and future directions
by: Laurence Si Chong Lok, et al.
Published: (2024-12-01)

The association between baseline physical and mental health and the risk of postacute sequelae of COVID-19 infection
by: Nikhilesh Kumar, et al.
Published: (2025-07-01)

Joint analysis of time-varying effect of vaccine and antiviral drug for preventing severe complications and mortality
by: Jialiang Jiang, et al.
Published: (2025-02-01)

Symptoms and pathophysiology of post-acute sequelae following COVID-19 (PASC): a cohort studyResearch in context
by: Olivier Robineau, et al.
Published: (2025-07-01)

Risk Factors for Seeking Medical Care Following Nirmatrelvir-Ritonavir (Paxlovid) Treatment for COVID-19: “Symptom Rebound”
by: Ashish Bhargava, et al.
Published: (2025-05-01)

Association between nirmatrelvir/ritonavir treatment and antibiotic prescribing in the outpatient setting among patients with COVID-19
by: Aisling R. Caffrey, et al.
Published: (2025-04-01)

MODERN DIRECTED ANTIVIRAL COVID-19 THERAPY: RESULTS OF MULTICENTER CLINICAL EFFECTIVENESS AND SAFETY STUDY OF FIXED NIRMATRELVIR+RITONAVIR COMBINATION
by: L. A. Balykova, et al.
Published: (2022-10-01)

Bioequivalence study of generic nirmatrelvir in healthy volunteers
by: R. A. Oseshnyuk, et al.
Published: (2023-05-01)

Consensus based recommendations for the management of post-COVID long-term sequelae (Long COVID): a regional perspective
by: Majid AlShamrani, et al.
Published: (2025-08-01)

Using machine learning involving diagnoses and medications as a risk prediction tool for post-acute sequelae of COVID-19 (PASC) in primary care
by: Seika Lee, et al.
Published: (2025-04-01)

Nirmatrelvir-ritonavir significantly reduces severe COVID-19 outcomes in diverse Taiwanese populations: Comprehensive evidence from a large-scale longitudinal cohort study in Taiwan
by: Fu-Der Wang, et al.
Published: (2025-06-01)

Impact of pre-existing comorbidities and multimorbidities, demography and viral variants on post-acute sequelae of COVID-19 (‘Long COVID’) in Dutch primary care: A retrospective cohort study
by: Matthijs S. Berends, et al.
Published: (2025-07-01)

Therapeutic options for the treatment of post-acute sequelae of COVID-19: a scoping review
by: Yu Bin Seo, et al.
Published: (2025-05-01)

Simultaneous Determination of Nirmatrelvir and Ritonavir in Human Plasma by HPLC-MS/MS
by: T. N. Komarov, et al.
Published: (2023-05-01)

Composite outcome of oral azvudine vs. nirmatrelvir-ritonavir in COVID-19 patients: a retrospective cohort study
by: Jingxia Chen, et al.
Published: (2025-04-01)

Paxlovid for the treatment of COVID-19: a systematic review and meta-analysis
by: Yu Wang, et al.
Published: (2024-08-01)

Immune Signatures in Post-Acute Sequelae of COVID-19 (PASC) and Myalgia/Chronic Fatigue Syndrome (ME/CFS): Insights from the Fecal Microbiome and Serum Cytokine Profiles
by: Martin Tobi, et al.
Published: (2025-06-01)

Real-world effectiveness of simnotrelvir-ritonavir versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19 during the omicron wave in China: a retrospective cohort study
by: Chuntao Li, et al.
Published: (2025-07-01)

Pharmacovigilance of Drug–Drug Interactions with Nirmatrelvir/Ritonavir
by: Victoria Hendrick, et al.
Published: (2024-10-01)

The effect of molnupiravir and nirmatrelvir on SARS-CoV-2 genome diversity in severe models of COVID-19
by: Rebekah Penrice-Randal, et al.
Published: (2025-05-01)

Prevalence, spectrum, and the relations between short-term and long-term post-acute sequelae of COVID-19 in children
by: Elena R. Meskina, et al.
Published: (2025-03-01)

New-onset cardiovascular diseases post SARS-CoV-2 infection in an urban population in the Bronx
by: Jason Y. Lu, et al.
Published: (2024-12-01)

Efficacy and safety of antiviral treatments for symptomatic COVID-19 outpatients: network meta-analysis and budget impact analysis
by: Giacomo Berti, et al.
Published: (2025-04-01)

Cost-effectiveness analysis of nirmatrelvir/ritonavir in adult patients at high risk of progressing to severe COVID-19
by: Carolina Moreno, et al.
Published: (2025-07-01)

Efficacy of Nirmatrelvir/ritonavir in reducing the risk of severe outcome in patients with SARS-CoV-2 infection: a real-life full-matched case-control study (SAVALO Study)
by: Ivan Gentile, et al.
Published: (2024-12-01)

The effectiveness of nirmatrelvir/ritonavir regimen in hospitalized renal transplant patients with prolonged COVID-19 infection: a multicenter clinical experience
by: Huanxi Zhang, et al.
Published: (2024-12-01)

Phase I Pharmacokinetics Study of Oral Administration of Esperavir® (INN: Molnupiravir) (LLC "PROMOMED RUS", Russia)
by: T. N. Komarov, et al.
Published: (2024-03-01)